Identifying crosstalk of mTOR signaling pathway of lobular breast carcinomas

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 10, 2012, Pages 1355-1361

  Sun, G ^a   Shan, M H ^a   Ma, B L ^a   Geng, Z L ^a   Alibiyati, A ^a   Zhong, H ^a   Wang, J ^a   Ren, G H ^a   Li, H T ^a   Dong, C ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Invasive lobular carcinoma; MTOR signaling pathway; Pathway crosstalk

Indexed keywords

ADIPOCYTOKINE; CELL ADHESION MOLECULE; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; SCLEROPROTEIN; MTOR PROTEIN, HUMAN; NAPHTHOQUINONE; PLUMBAGIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; BREAST CARCINOMA; CELL JUNCTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; MATHEMATICAL MODEL; MICROARRAY ANALYSIS; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; BREAST TUMOR; FEMALE; HUMAN; LUNG CARCINOMA; METABOLISM; PHYSIOLOGY;

ADIPOKINES; AUTOPHAGY; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; NAPHTHOQUINONES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84871860035     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ORVIETO E, MAIORANO E, BOTTIGLIERI L, MAISONNEUVE P, ROTMENSZ N, GALIMBERTI V, LUINI A, BRENELLI F, GATTI G, VIALE G. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008; 113: 1511-1520.
2. GREEN AR, YOUNG P, KRIVINSKAS S, RAKHA EA, CLAIRE PAISH E, POWE DG, ELLIS IO. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. Histopathology 2009; 54: 419-427.
3. RIGGINS RB, LAN JPJ, KLIMACH U, ZWART A, CAVALLI LR, HADDAD BR, CHEN L, GONG T, XUAN J, ETHIER SP, CLARKE R. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 2008; 68: 8908-8917.
4. MCAULIFFE PF, MERIC-BERNSTAM F, MILLS GB, GONZALEZ-ANGULO AM. Decipher ing the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010; 10(Suppl 3): S59-65.
5. CASTANEDA CA, CORTES-FUNES H, GOMEZ HL, CIRUELOS EM. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 2010; 29: 751-759.
6. NOH WC, KIM YH, KIM MS, KOH JS, KIM HA, MOON NM, PAIK NS. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008; 110: 477-483. (Pubitemid 351962593)
7. BOULAY A, RUDLOFF J, YE J, ZUMSTEIN-MECKER S, O'REILLY T, EVANS DB, CHEN S, LANE HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11: 5319-5328. (Pubitemid 41003721)
8. ALBERT JM, KIM KW, CAO C, LU B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006; 5: 1183-1189. (Pubitemid 43881310)
9. CHEN Y, RODRIK V, FOSTER DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005; 24: 672-679. (Pubitemid 40188571)
10. TURASHVILI G, BOUCHAL J, BAUMFORTH K, WEI W, DZIECHCIARKOVA M, EHRMANN J, KLEIN J, FRIDMAN E, SKARDA J, SROVNAL J, HAJDUCH M, MURRAY P, KOLAR Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7: 55.
11. KANEHISA M. The KEGG database. 2002.
12. KESHAVA PRASAD T, GOEL R, KANDASAMY K, KEERTHIKUMAR S, KUMAR S, MATHIVANAN S, TELIKICHERLA D, RAJU R, SHAFREEN B, VENUGOPAL A, BALAKRISHNAN L, MARIMUTHU A, BANERJEE S, SOMANATHAN DS, SEBASTIAN A, RANI S, RAY S, HARRYS KISHORE CJ, KANTH S, AHMED M, KASHYAP MK, MOHMOOD R, RAMACHANDRA YL, KRISHNA V, RAHIMAN BA, MOHAN S, RANGANATHAN P, RAMABADRAN S, CHAERKADY R, PANDEY A. Human protein reference database-2009 update. Nucleic Acids Res 2009; 37(Database issue): D767-772.
13. STARK C, BREITKREUTZ B J, CHATR-ARYAMONTRI A, BOUCHER L, OUGHTRED R, LIVSTONE M S, NIXON J, VAN AUKEN K, WANG X, SHI X, REGULY T, RUST JM, WINTER A, DOLINSKI K, TYERS M. The BioGRID Interaction Database: 2011 update. Nucleic Acids Res 2011; 39(Suppl 1): D698-704.
14. LIVASY CA, KARACA G, NANDA R, TRETIAKOVA MS, OLOPADE OI, MOORE DT, PEROU CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271. (Pubitemid 43117611)
15. SMYTH GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
16. DRAGHICI S, KHATRI P, TARCA AL, AMIN K, DONE A, VOICHITA C, GEORGESCU C, ROMERO R. A systems biology approach for pathway level analysis. Genome Res 2007; 17: 1537-1545. (Pubitemid 47529438)
17. TAVAZOIE S, HUGHES J D, CAMPBELL MJ, CHO R J, CHURCH GM. Systematic determination of genetic network architecture.Nat Genet 1999; 22: 281-285. (Pubitemid 29297256)
18. DRAGHICI S, KHATRI P, MARTINS R P, OSTERMEIER G C,KRAWETZ SA. Global functional profiling of gene expression. Genomics 2003; 81: 98-104. (Pubitemid 36298600)
19. LIU ZP, WANG Y, ZHANG X S, CHEN L. Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Syst Biol 2010; 4(Suppl 2): S11.
20. SILVA L D, PARRY S, REID L, KEITH P, WADDELL N, KOSSAI M, CLARKE C, LAKHANI SR, SIMPSON PT. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008; 32: 773-783. (Pubitemid 351600817)
21. SARRIÓ D, PÉREZ-MIES B, HARDISSON D, MORENOBUENO G, SUÁREZ A, CANO A, MARTÍN-PÉREZ J, GAMALLO C, PALACIOS J. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23: 3272-3283. (Pubitemid 38669817)
22. TAKEUCHI T, ADACHI Y, NAGAYAMA T, FURIHATA M. Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance. Virchows Arch 2011; 459: 291-297.
23. MINGO-SION AM, FERGUSON HA, KOLLER E, REYLAND ME, BERG CLVD. PKC|Ä and mTOR interact to regulate stress and IGF-I induced IRS-1 Ser 312 phosphorylation in breast cancer cells. Breast cancer research and treatment 2005; 91: 259-269. (Pubitemid 40896571)
24. TALIAFERRO-SMITH L, NAGALINGAM A, ZHONG D, ZHOU W, SAXENA N, SHARMA D. LKB1 is required for adiponectin-mediated modulation of AMPKCS6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009; 28: 2621-2633.
25. JARDÉ T, PERRIER S, VASSON MP, CALDEFIE-CHÉZET F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cance 2011; 47: 33-43.
26. GUO S, LIU M, GONZALEZ-PEREZ RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815: 197-213.
27. MUNGAMURI SK, YANG X H, THOR AD, SOMASUNDARAM K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66: 4715-4724.
28. EFFERSON C L, WINKELMANN C T, WARE C, SULLIVAN T, GIAMPAOLI S, TAMMAM J, PATEL S, MESITI G, REILLY JF, GIBSON RE, BUSER C, YEATMAN T, COPPOLA D, WINTER C, CLARK EA, DRAETTA GF, STRACK PR, MAJUMDER PK. Downregulation of Notch pathway by a gammasecretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 2010; 70: 2476-2484.
29. KIM K W, MUTTER RW, CAO C, ALBERT JM, FREEMAN M, HALLAHAN DE, LU B, Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 2006; 281: 36883-36890. (Pubitemid 46042156)
30. KUO PL, HSU YL, CHO CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.Mol Cancer Ther 2006; 5: 3209-3221.
31. COLLU GM, BRENNAN K. Cooperation between Wnt and Notch signalling in human breast cancer. Breast Cancer Res 2007; 9: 105.
32. ZHANG Y, WANG F, HAN L, WU Y, LI S, YANG X, WANG Y, REN F, ZHAI Y, WANG D, JIA B, XIA Y, CHANG Z. GABARAPL1 Negatively Regulates Wnt/β-catenin Signaling by Mediating Dvl2 Degradation through the Autophagy Pathway. Cell Physiol Biochem 2011; 27: 503-512.
33. GAO C, CAO W, BAO L, ZUO W, XIE G, CAI T, FU W, ZHANG J, WU W, ZHANG X, CHEN YG. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol 2010; 12: 781-790.